IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terrill K. McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Veena Shankaran(University of Washington), Erin Murphy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), David R. Kaufman(Gates (United States)), Shijun Kang(Nanfang Hospital), Jonathan D. Cheng(Princeton University), Tanguy Y. Seiwert(Georgetown University)
Cited by 3,853
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k